Clinical Trials Logo

Filter by:
NCT ID: NCT04242446 Completed - Clinical trials for Hidradenitis Suppurativa

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

BE HEARD I
Start date: February 19, 2020
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

NCT ID: NCT04242199 Active, not recruiting - Clinical trials for HepatoCellular Carcinoma

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Start date: September 4, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors

NCT ID: NCT04241562 Completed - TMD Clinical Trials

Validation of a Novel Cortical Biomarker Signature for Pain

PREDICT
Start date: November 4, 2020
Phase:
Study type: Observational

The study aims to undertake analytical validation of an brain biomarker in healthy participants experiencing a model of sustained temporomandibular pain. The biomarker could detect participants at greater risk of developing more severe pain.

NCT ID: NCT04241185 Recruiting - Clinical trials for Urinary Bladder Neoplasms

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Start date: May 19, 2020
Phase: Phase 3
Study type: Interventional

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

NCT ID: NCT04241068 Active, not recruiting - Alzheimer's Disease Clinical Trials

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Start date: March 2, 2020
Phase: Phase 3
Study type: Interventional

The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received placebo (i.e. treatment-naïve participants).

NCT ID: NCT04239703 Recruiting - Clinical trials for Kidney Transplant Rejection

Trifecta-Kidney cfDNA-MMDx Study

Start date: December 1, 2019
Phase:
Study type: Observational

Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.

NCT ID: NCT04238819 Active, not recruiting - Clinical trials for Refractory Solid Tumor

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Start date: November 9, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment. For each participant, the study is estimated to last up to 2 years.

NCT ID: NCT04238390 Withdrawn - Clinical trials for Bacteremia Caused by Gram-Negative Bacteria

Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection

MERINO III
Start date: January 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether ceftolozane-tazobactam is as effective as meropenem with respect to 30 day mortality in the treatment of bloodstream infection due to third-generation cephalosporin non-susceptible Enterobacterales or a known chromosomal AmpC-producing Enterobacterales (Enterobacter spp., Citrobacter freundii, Morganella morganii, Providencia spp. or Serratia marcescens).

NCT ID: NCT04236856 Completed - Headache Clinical Trials

CorPath® GRX Neuro Study

Start date: August 21, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate the effectiveness and safety of robotic-assisted endovascular embolization procedures compared to objective performance criteria for traditional, manual operation based on the scientific literature.

NCT ID: NCT04236609 Active, not recruiting - Clinical trials for Coronary Artery Disease

Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global

ABILITY
Start date: June 15, 2020
Phase: N/A
Study type: Interventional

To compare in diabetic patients eligible for percutaneous coronary intervention (PCI) with minimal exclusion criteria, the efficacy and safety of Abluminus DES+ sirolimus- eluting stents (SES) versus XIENCE Everolimus-Eluting Stents (EES). At least 40% of patients are expected to be affected by multivessel coronary artery disease and 30% with acute coronary syndrome